

**Supplementary Table 1.** Summary of the number of patients by treatment site

Site/Institutional Review Board (IRB) approval	Enrolled	cDMARD+anti-TNF (n=73)		Multiple cDMARDs (n=134)		Total (n=207)	
		Complete	Discont	Complete	Discont	Complete	Discont
Konkuk University Medical Center/ Konkuk University Medical Center (KUH1010880)	7	1 (14.3)	1 (14.3)	2 (28.6)	3 (42.9)	3 (42.9)	4 (57.1)
Samsung Medical Center/Samsung Medical Center (SMC 2017-06-046)	4	0 (0)	0 (0)	2 (50.0)	2 (50.0)	2 (50.0)	2 (50.0)
Hanyang University Medical Center/ Hanyang University Medical Center (HYUH 2017-06-008)	23	12 (52.2)	2 (8.7)	8 (34.8)	1 (4.4)	20 (87.0)	3 (13.0)
Inje University Ilsan Paik Hospital/ Inje University Ilsan Paik Hospital (ISPAIK 2017-06-004)	4	0 (0)	1 (25.0)	2 (50.0)	1 (25.0)	2 (50.0)	2 (50.0)
Gangnam Severance Hospital/Gangnam Severance Hospital (3-2017-0262)	1	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	1 (100.0)
Hanyang University Guri Hospital/ Hanyang University Guri Hospital (GURI 2017-06-013)	9	1 (11.1)	0 (0)	7 (77.8)	1 (11.1)	8 (88.9)	1 (11.1)
Pusan National University Hospital/ Pusan National University Hospital (H-1707-018-057)	1	0 (0)	0 (0)	1 (100.0)	0 (0)	1 (100.0)	0 (0)
Inje University Busan Paik Hospital/ Inje University Busan Paik Hospital (17-0095)	25	6 (24.0)	4 (16.0)	7 (28.0)	8 (32.0)	13 (52.0)	12 (48.0)
Pusan National University Yangsan Hospital/Pusan National University Yangsan Hospital (02-2017-020)	50	6 (12.0)	7 (14.0)	28 (56.0)	9 (18.0)	34 (68.0)	16 (32.0)
Keimyung University Dongsan Hospital/ Keimyung University Dongsan Hospital (DSMC 2017-06-025)	35	7 (20.0)	2 (5.7)	16 (45.7)	10 (28.6)	23 (65.7)	12 (34.3)
Daegu Catholic University Medical Center/Daegu Catholic University Medical Center (CR-17-067-L)	17	3 (17.7)	2 (11.8)	10 (58.8)	2 (11.8)	13 (76.5)	4 (23.5)
Inje University Haeundae Paik Hospital/ Inje University Haeundae Paik Hospital (HPIRB 2017-06-015)	3	0 (0)	0 (0)	3 (100.0)	0 (0)	3 (100.0)	0 (0)
Nowon Eulji Medical Center, Eulji University/Nowon Eulji Medical Center, Eulji University (EMCS 2017-06-013)	11	4 (36.4)	1 (9.1)	6 (54.6)	0 (0)	10 (90.9)	1 (9.1)
Dong-A University Hospital/Dong-A University Hospital (DAUHIB-17-177)	1	0 (0)	0 (0)	0 (0)	1 (100.0)	0 (0)	1 (100.0)
Gyeongsang National University Hospital/Gyeongsang National University Hospital (GNUH 2017-08-002)	16	7 (43.8)	6 (37.5)	3 (18.8)	0 (0)	10 (62.5)	6 (37.5)
<b>Total (15 treatment sites)</b>	<b>207</b>	<b>47 (64.4)</b>	<b>26 (35.6)</b>	<b>95 (70.9)</b>	<b>39 (29.1)</b>	<b>142 (68.6)</b>	<b>65 (31.4)</b>

Values are presented as number only or number (%). Percentages are based on the number of patients enrolled at each treatment site. cDMARD: conventional disease-modifying anti-rheumatic drug, TNF: tumor necrosis factor, Complete: completed study, Discont: discontinued study.

**Supplementary Table 2.** Medications taken to treat rheumatoid arthritis during the study (per-protocol set)

Concomitant medication	cDMARD+anti-TNF (n=45)	Multiple cDMARDs (n=91)	p-value
cDMARDs			
Methotrexate	42 (93.3)	79 (86.8)	0.384
Leflunomide	0 (0)	39 (42.9)	<0.001
Tacrolimus	0 (0)	45 (49.1)	<0.001
Ciclosporin	0 (0)	1 (1.1)	<0.001
Anti-TNF agents			
Adalimumab	28 (62.2)	0 (0)	<0.001
Etanercept	9 (20.0)	0 (0)	<0.001
Golimumab	4 (8.9)	0 (0)	<0.001
Infliximab	4 (8.9)	0 (0)	<0.001
Systemic corticosteroids			
Methylprednisolone	11 (24.4)	45 (49.5)	0.009
Prednisolone	18 (40.0)	22 (24.2)	0.088
Triamcinolone	7 (15.6)	18 (19.8)	0.716
Dexamethasone	1 (2.2)	2 (2.2)	>0.999
Deflazacort	0 (0.00)	1 (1.1)	<0.001
Musculoskeletal system agents			
Celecoxib	27 (60.0)	50 (54.9)	0.707
Nabumetone	2 (4.4)	5 (5.5)	>0.999
Aceclofenac	3 (6.7)	5 (5.5)	>0.999
Meloxicam	3 (6.7)	4 (4.4)	0.685
Naproxen and esomeprazole	1 (2.2)	3 (3.3)	>0.999
Naproxen	2 (4.4)	0 (0.0)	0.108
Other	6 (13.3)	6 (6.9)	0.211
Bucillamine	0 (0.0)	3 (3.3)	0.551
Avocado/soyabean oil, unsaponifiables	1 (2.2)	0 (0.0)	0.331
Risedronic acid	1 (2.2)	0 (0.0)	0.331

Values are presented as number (%). Anti-TNF: anti-tumor necrosis factor agent, cDMARD: conventional disease-modifying anti-rheumatic drug.